Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.010 +0.040 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
Via Benzinga
Topics Stocks
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma: Q3 Earnings Insights
 
Via Benzinga
A Preview Of Lantern Pharma's Earnings
 
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries. 
Via InvestorPlace
Topics Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
From Lantern Pharma
Via Business Wire
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
The 3 Most Undervalued AI Penny Stocks to Buy in December
These AI penny stocks offer substantial returns to investors as the market continues to grow at a rapid pace. 
Via InvestorPlace
Topics Artificial Intelligence
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
The 7 Most Undervalued AI Penny Stocks to Buy: October 2023
Unlock exponential growth with the next big undervalued AI penny stocks to buy, offering tremendous upside ahead. 
Via InvestorPlace
Topics Artificial Intelligence
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
From Lantern Pharma
Via Business Wire
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
From Lantern Pharma Inc.
Via Business Wire
The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023
Here are three machine-learning stocks that may be ready to move much higher when investor sentiment changes. 
Via InvestorPlace
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
3 AI Stocks That Still Trade Under $10 Per Share
With the artificial intelligence (AI) boom ramping up, check out this short list of hot AI stocks under $10. 
Via InvestorPlace
Topics Artificial Intelligence
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
From Lantern Pharma Inc.
Via Business Wire
The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023
Machine learning stocks still have a lot of room left to rise despite a short-term pullback in their stock prices. 
Via InvestorPlace
8 Best Artificial Intelligence Stocks Under $10
If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more. 
Via MarketBeat
Topics Artificial Intelligence Economy
The 3 Most Undervalued AI Penny Stocks to Buy Now: August 2023
Not only would I take full advantage of the pullbacks in heavyweight AI stocks, I’d also take advantage of the drops in top AI penny stocks. 
Via InvestorPlace
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.